Natural history of stage II/III breast cancer, bone metastasis and the impact of adjuvant zoledronate on distribution of recurrences
Aim: The prognosis for women with breast cancer has improved markedly over recent decades. However, mortality from breast cancer remains high and, for those developing metastatic disease, curative therapy is not possible. Here, we report the frequency and distribution of disease recurrence(s) in a l...
Main Authors: | Stella D'Oronzo, Walter Gregory, Simon Nicholson, Yuen Khong Chong, Janet Brown, Robert Coleman |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-06-01
|
Series: | Journal of Bone Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S221213742100021X |
Similar Items
-
Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions
by: Christopher N. George, et al.
Published: (2020-12-01) -
Evaluating the Clinical Efficacy of Zoledronic Acid in the Prevention and Treatment of Osteoporosis in Postmenopausal Women, Compared with Conventional Medications
by: Fatemeh Rostami-Golmohammadi, et al.
Published: (2015-02-01) -
Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer
by: Elie Akoury, et al.
Published: (2019-02-01) -
Bone-seeking nanoplatform co-delivering cisplatin and zoledronate for synergistic therapy of breast cancer bone metastasis and bone resorption
by: Yanjuan Huang, et al.
Published: (2020-12-01) -
Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis
by: Elie Akoury, et al.
Published: (2019-08-01)